Cerus Corporation (CERS)

Market Cap	515.90M +105.5%
Revenue (ttm)	221.55M +15.1%
Net Income	-6.78M
EPS	-0.03
Shares Out	201.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	379,544
Open	2.560
Previous Close	2.590
Day's Range	2.525 - 2.580
52-Week Range	1.170 - 3.470
Beta	1.80
Analysts	Strong Buy
Price Target	5.13 (+100.39%)
Earnings Date	Jul 30, 2026

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma do...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 1997
• Employees: 275
• Stock Exchange: NASDAQ
• Ticker Symbol: CERS
• Website: https://www.cerus.com

Financial Performance

In 2025, Cerus's revenue was $206.13 million, an increase of 14.35% compared to the previous year's $180.27 million. Losses were -$15.63 million, -25.29% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for CERS stock is "Strong Buy." The 12-month stock price target is $5.13, which is an increase of 100.39% from the latest price.

Price Target

$5.13

(100.39% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 8, 2026

Data Sources Report a data error